MDGL Overview

Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a liver disease with high unmet medical need. The Company’s medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-b agonist designed to target key underlying causes of MASH. Rezdiffra is the medication approved by the United States Food and Drug Administration (FDA) for the treatment of MASH with moderate to advanced fibrosis (consistent with stages F2 to F3). Rezdiffra is a prescribed medicine used along with diet and exercise to treat adults with nonalcoholic steatohepatitis (NASH) with moderate to advanced liver scarring (fibrosis), but not with cirrhosis of the liver. An ongoing Phase III outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (consistent with stage F4c).

Wall Street analysts forecast MDGL stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MDGL is636.22 USD with a low forecast of 527.00 USD and a high forecast of 900.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Madrigal Pharmaceuticals Inc revenue for the last quarter amounts to 287.00M USD, increased 362.03 % YoY.

Madrigal Pharmaceuticals Inc. EPS for the last quarter amounts to -5.08 USD, increased 3.25 % YoY.

Madrigal Pharmaceuticals Inc (MDGL) has 528 emplpoyees as of January 31 2026.

Today MDGL has the market capitalization of 11.00B USD.